UA79448C2 - Derivatives of 3-aryl-2,5-dihydroxy-1,4-benzoquinone, method for synthesis and pharmaceutical composition - Google Patents
Derivatives of 3-aryl-2,5-dihydroxy-1,4-benzoquinone, method for synthesis and pharmaceutical composition Download PDFInfo
- Publication number
- UA79448C2 UA79448C2 UA20040907252A UA20040907252A UA79448C2 UA 79448 C2 UA79448 C2 UA 79448C2 UA 20040907252 A UA20040907252 A UA 20040907252A UA 20040907252 A UA20040907252 A UA 20040907252A UA 79448 C2 UA79448 C2 UA 79448C2
- Authority
- UA
- Ukraine
- Prior art keywords
- formula
- branched
- linear
- benzoquinone
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 45
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 79
- 229940005561 1,4-benzoquinone Drugs 0.000 claims abstract description 31
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 24
- 125000003118 aryl group Chemical group 0.000 claims abstract description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 19
- -1 benzhydryl group Chemical group 0.000 claims abstract description 15
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 15
- 125000002252 acyl group Chemical group 0.000 claims abstract description 13
- IIBSKZLEQXFSRM-UHFFFAOYSA-N 2,5-dihydroxy-3-(4-methoxyphenyl)-6-naphthalen-2-ylcyclohexa-2,5-diene-1,4-dione Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C(C=2C=C3C=CC=CC3=CC=2)=C(O)C1=O IIBSKZLEQXFSRM-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000004342 dicyclopropylmethyl group Chemical group [H]C1([H])C([H])([H])C1([H])C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 5
- HEMZKGQLXULANP-UHFFFAOYSA-N 2,5-dihydroxy-3-naphthalen-2-yl-6-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(O)=C(C=2C=C3C=CC=CC3=CC=2)C(=O)C(O)=C1C1=CC=CC=C1 HEMZKGQLXULANP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract 3
- 239000002253 acid Substances 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000000654 additive Substances 0.000 claims description 15
- 230000000996 additive effect Effects 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000006684 polyhaloalkyl group Polymers 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical group O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 4
- VTFRCXNKWWTVCR-UHFFFAOYSA-N 2,5-dihydroxy-3-(4-methoxyphenyl)-6-(2-phenylethenyl)cyclohexa-2,5-diene-1,4-dione Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C(C=CC=2C=CC=CC=2)=C(O)C1=O VTFRCXNKWWTVCR-UHFFFAOYSA-N 0.000 claims description 4
- DCBQNQJIQLNPOO-UHFFFAOYSA-N 2-(4-chlorophenyl)-3,6-dihydroxy-5-naphthalen-2-ylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(O)=C(C=2C=C3C=CC=CC3=CC=2)C(=O)C(O)=C1C1=CC=C(Cl)C=C1 DCBQNQJIQLNPOO-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims description 3
- UYGHUZALAJWNDW-UHFFFAOYSA-N 2-(4-bromophenyl)-3,6-dihydroxy-5-naphthalen-2-ylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(O)=C(C=2C=C3C=CC=CC3=CC=2)C(=O)C(O)=C1C1=CC=C(Br)C=C1 UYGHUZALAJWNDW-UHFFFAOYSA-N 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 230000003831 deregulation Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
- PCMWVXNZRQRPBY-UHFFFAOYSA-N 2-(4-bromophenyl)-3,6-dihydroxy-5-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(O)=C(C=2C=CC=CC=2)C(=O)C(O)=C1C1=CC=C(Br)C=C1 PCMWVXNZRQRPBY-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000010933 acylation Effects 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 230000002152 alkylating effect Effects 0.000 claims description 2
- 230000029936 alkylation Effects 0.000 claims description 2
- 238000005804 alkylation reaction Methods 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 229910052717 sulfur Chemical group 0.000 claims description 2
- 239000011593 sulfur Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000002844 melting Methods 0.000 description 29
- 230000008018 melting Effects 0.000 description 29
- 239000000047 product Substances 0.000 description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 229940117916 cinnamic aldehyde Drugs 0.000 description 16
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 102000003746 Insulin Receptor Human genes 0.000 description 11
- 108010001127 Insulin Receptor Proteins 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 108091008611 Protein Kinase B Proteins 0.000 description 10
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000001994 activation Methods 0.000 description 6
- 150000004002 naphthaldehydes Chemical class 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- FCZGHPGTZRTDNN-UHFFFAOYSA-N 1,2-bis(trimethylsilyloxy)ethenoxy-trimethylsilane Chemical group C[Si](C)(C)OC=C(O[Si](C)(C)C)O[Si](C)(C)C FCZGHPGTZRTDNN-UHFFFAOYSA-N 0.000 description 3
- VQVBNWUUKLBHGI-UHFFFAOYSA-N 2-(4-bromophenyl)acetyl chloride Chemical compound ClC(=O)CC1=CC=C(Br)C=C1 VQVBNWUUKLBHGI-UHFFFAOYSA-N 0.000 description 3
- SIOJFYRPBYGHOO-UHFFFAOYSA-N 2-(4-fluorophenyl)acetyl chloride Chemical compound FC1=CC=C(CC(Cl)=O)C=C1 SIOJFYRPBYGHOO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- VLUMOWNVWOXZAU-VQHVLOKHSA-N (e)-2-methyl-3-phenylprop-2-enal Chemical compound O=CC(/C)=C/C1=CC=CC=C1 VLUMOWNVWOXZAU-VQHVLOKHSA-N 0.000 description 2
- YSIYEWBILJZDQH-OWOJBTEDSA-N (e)-3-(4-fluorophenyl)prop-2-enal Chemical compound FC1=CC=C(\C=C\C=O)C=C1 YSIYEWBILJZDQH-OWOJBTEDSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- YYIGFJJQBJFQAE-UHFFFAOYSA-N 2,5-dihydroxy-3,6-dinaphthalen-2-ylcyclohexa-2,5-diene-1,4-dione Chemical compound C1=CC=CC2=CC(C3=C(C(C(=C(O)C3=O)C=3C=C4C=CC=CC4=CC=3)=O)O)=CC=C21 YYIGFJJQBJFQAE-UHFFFAOYSA-N 0.000 description 2
- WIHSAOYVGKVRJX-UHFFFAOYSA-N 2-(2-chlorophenyl)acetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1Cl WIHSAOYVGKVRJX-UHFFFAOYSA-N 0.000 description 2
- PYPMKORNJLTHGP-UHFFFAOYSA-N 2-(3-chlorophenyl)acetyl chloride Chemical compound ClC(=O)CC1=CC=CC(Cl)=C1 PYPMKORNJLTHGP-UHFFFAOYSA-N 0.000 description 2
- UMQUIRYNOVNYPA-UHFFFAOYSA-N 2-(4-chlorophenyl)acetyl chloride Chemical compound ClC(=O)CC1=CC=C(Cl)C=C1 UMQUIRYNOVNYPA-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229930015698 phenylpropene Natural products 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- HJWLCRVIBGQPNF-UHFFFAOYSA-N prop-2-enylbenzene Chemical compound C=CCC1=CC=CC=C1 HJWLCRVIBGQPNF-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- UAIHPMFLFVHDIN-UHFFFAOYSA-K trichloroosmium Chemical compound Cl[Os](Cl)Cl UAIHPMFLFVHDIN-UHFFFAOYSA-K 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XYRAWLRFGKLUMW-OWOJBTEDSA-N (e)-3-(4-bromophenyl)prop-2-enal Chemical compound BrC1=CC=C(\C=C\C=O)C=C1 XYRAWLRFGKLUMW-OWOJBTEDSA-N 0.000 description 1
- HONRSHHPFBMLBT-OWOJBTEDSA-N (e)-3-(4-chlorophenyl)prop-2-enal Chemical compound ClC1=CC=C(\C=C\C=O)C=C1 HONRSHHPFBMLBT-OWOJBTEDSA-N 0.000 description 1
- LGDJTQJRMBMCIS-ONEGZZNKSA-N (e)-3-naphthalen-2-ylprop-2-enal Chemical group C1=CC=CC2=CC(/C=C/C=O)=CC=C21 LGDJTQJRMBMCIS-ONEGZZNKSA-N 0.000 description 1
- IEARORYJISZKGK-VQHVLOKHSA-N (e)-3-phenylbut-2-enal Chemical compound O=C\C=C(/C)C1=CC=CC=C1 IEARORYJISZKGK-VQHVLOKHSA-N 0.000 description 1
- NJQSQRLNJKDGCQ-OWOJBTEDSA-N (e)-4,4-dicyclopropylbut-2-enal Chemical compound C1CC1C(/C=C/C=O)C1CC1 NJQSQRLNJKDGCQ-OWOJBTEDSA-N 0.000 description 1
- JKVGGKKXZOZXMP-UHFFFAOYSA-N 1-hydroxy-3-naphthalen-2-ylpropan-2-one Chemical compound C1=CC=CC2=CC(CC(=O)CO)=CC=C21 JKVGGKKXZOZXMP-UHFFFAOYSA-N 0.000 description 1
- QLCZRWKIQPLYFS-UHFFFAOYSA-N 1-hydroxy-3-phenylpropan-2-one Chemical compound OCC(=O)CC1=CC=CC=C1 QLCZRWKIQPLYFS-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
- BEJUPXYIJCJIDV-UHFFFAOYSA-N 2,5-dihydroxy-3-phenyl-6-(2-phenylcyclopropyl)cyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(O)=C(C=2C=CC=CC=2)C(=O)C(O)=C1C1CC1C1=CC=CC=C1 BEJUPXYIJCJIDV-UHFFFAOYSA-N 0.000 description 1
- NKWUSHJRXXYSHL-UHFFFAOYSA-N 2,5-dihydroxy-3-phenyl-6-(2-phenylethynyl)cyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(O)=C(C=2C=CC=CC=2)C(=O)C(O)=C1C#CC1=CC=CC=C1 NKWUSHJRXXYSHL-UHFFFAOYSA-N 0.000 description 1
- FUZNMUDUTLEWOR-UHFFFAOYSA-N 2-(2,2-diphenylethenyl)-3,6-dihydroxy-5-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(O)=C(C=2C=CC=CC=2)C(=O)C(O)=C1C=C(C=1C=CC=CC=1)C1=CC=CC=C1 FUZNMUDUTLEWOR-UHFFFAOYSA-N 0.000 description 1
- KCMMYTBNFDPNMT-UHFFFAOYSA-N 2-(2-chlorophenyl)-3,6-dihydroxy-5-naphthalen-2-ylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(O)=C(C=2C=C3C=CC=CC3=CC=2)C(=O)C(O)=C1C1=CC=CC=C1Cl KCMMYTBNFDPNMT-UHFFFAOYSA-N 0.000 description 1
- PRDHYXSRPLECPP-UHFFFAOYSA-N 2-(3-chlorophenyl)-3,6-dihydroxy-5-naphthalen-2-ylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(O)=C(C=2C=C3C=CC=CC3=CC=2)C(=O)C(O)=C1C1=CC=CC(Cl)=C1 PRDHYXSRPLECPP-UHFFFAOYSA-N 0.000 description 1
- KLLOEEOCCIWPRD-UHFFFAOYSA-N 2-(4-fluorophenyl)-3,6-dihydroxy-5-naphthalen-2-ylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(O)=C(C=2C=C3C=CC=CC3=CC=2)C(=O)C(O)=C1C1=CC=C(F)C=C1 KLLOEEOCCIWPRD-UHFFFAOYSA-N 0.000 description 1
- FYXZTVPBFJQFBO-UHFFFAOYSA-N 2-(4-nitrophenyl)acetyl chloride Chemical compound [O-][N+](=O)C1=CC=C(CC(Cl)=O)C=C1 FYXZTVPBFJQFBO-UHFFFAOYSA-N 0.000 description 1
- XGWCOBLCRATZKT-UHFFFAOYSA-N 2-(4-phenoxyphenyl)acetyl chloride Chemical compound C1=CC(CC(=O)Cl)=CC=C1OC1=CC=CC=C1 XGWCOBLCRATZKT-UHFFFAOYSA-N 0.000 description 1
- NRQMKIVIZWBJNU-UHFFFAOYSA-N 2-(6-bromonaphthalen-2-yl)-3,6-dihydroxy-5-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(O)=C(C=2C=C3C=CC(Br)=CC3=CC=2)C(=O)C(O)=C1C1=CC=CC=C1 NRQMKIVIZWBJNU-UHFFFAOYSA-N 0.000 description 1
- FEVJJJQOPGZSIG-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]acetyl chloride Chemical compound FC(F)(F)C1=CC=CC(CC(Cl)=O)=C1 FEVJJJQOPGZSIG-UHFFFAOYSA-N 0.000 description 1
- JRMAQQQTXDJDNC-UHFFFAOYSA-M 2-ethoxy-2-oxoacetate Chemical compound CCOC(=O)C([O-])=O JRMAQQQTXDJDNC-UHFFFAOYSA-M 0.000 description 1
- PJKVFARRVXDXAD-UHFFFAOYSA-N 2-naphthaldehyde Chemical compound C1=CC=CC2=CC(C=O)=CC=C21 PJKVFARRVXDXAD-UHFFFAOYSA-N 0.000 description 1
- QEJGMKHQXSZCOS-UHFFFAOYSA-N 2-naphthalen-2-ylacetyl chloride Chemical compound C1=CC=CC2=CC(CC(=O)Cl)=CC=C21 QEJGMKHQXSZCOS-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- GUGQQGROXHPINL-UHFFFAOYSA-N 2-oxobutanoyl chloride Chemical compound CCC(=O)C(Cl)=O GUGQQGROXHPINL-UHFFFAOYSA-N 0.000 description 1
- JMZMVURYVHXGKK-UHFFFAOYSA-N 2-pyridin-2-ylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=N1 JMZMVURYVHXGKK-UHFFFAOYSA-N 0.000 description 1
- MWAFWBDWAWZJGK-UHFFFAOYSA-N 3,3-diphenylprop-2-enal Chemical compound C=1C=CC=CC=1C(=CC=O)C1=CC=CC=C1 MWAFWBDWAWZJGK-UHFFFAOYSA-N 0.000 description 1
- DKOUYOVAEBQFHU-NSCUHMNNSA-N 3-(4-Methylphenyl)-2-propenal Chemical compound CC1=CC=C(\C=C\C=O)C=C1 DKOUYOVAEBQFHU-NSCUHMNNSA-N 0.000 description 1
- HYCDCKWWJCPUNT-UHFFFAOYSA-N 3-[4-(trifluoromethyl)phenyl]prop-2-enal Chemical compound FC(F)(F)C1=CC=C(C=CC=O)C=C1 HYCDCKWWJCPUNT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- JRKNFFXCEJDBAZ-UHFFFAOYSA-N 3-hydroxy-4-naphthalen-2-ylpyran-2,5-dione Chemical compound O=C1COC(=O)C(O)=C1C1=CC=C(C=CC=C2)C2=C1 JRKNFFXCEJDBAZ-UHFFFAOYSA-N 0.000 description 1
- JJBQGUUWJFMWEE-UHFFFAOYSA-N 3-hydroxy-4-phenylpyran-2,5-dione Chemical compound O=C1COC(=O)C(O)=C1C1=CC=CC=C1 JJBQGUUWJFMWEE-UHFFFAOYSA-N 0.000 description 1
- OQMDXZQTUXXEQL-UHFFFAOYSA-N 4-(4-chlorophenyl)-3-hydroxypyran-2,5-dione Chemical compound O=C1COC(=O)C(O)=C1C1=CC=C(Cl)C=C1 OQMDXZQTUXXEQL-UHFFFAOYSA-N 0.000 description 1
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
- DLLDUYJRQNTEOR-UHFFFAOYSA-N 6-bromonaphthalene-2-carbaldehyde Chemical compound C1=C(C=O)C=CC2=CC(Br)=CC=C21 DLLDUYJRQNTEOR-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- QKRIEOXJEIFTNZ-UHFFFAOYSA-N O=C1C(=CC=2C=C3C=CC=CC3=CC=2)OC(=O)C(O)=C1C1=CC=C(Cl)C=C1 Chemical compound O=C1C(=CC=2C=C3C=CC=CC3=CC=2)OC(=O)C(O)=C1C1=CC=C(Cl)C=C1 QKRIEOXJEIFTNZ-UHFFFAOYSA-N 0.000 description 1
- FGZGRWHWQMDDDG-UHFFFAOYSA-N OC=1C(OC(C(C=1C1=CC=CC=C1)=O)=CC=CC1=CC=CC=C1)=O Chemical compound OC=1C(OC(C(C=1C1=CC=CC=C1)=O)=CC=CC1=CC=CC=C1)=O FGZGRWHWQMDDDG-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- HYJZOIJTBMPKPU-UHFFFAOYSA-N [4-acetyloxy-2-(4-bromophenyl)-5-naphthalen-2-yl-3,6-dioxocyclohexa-1,4-dien-1-yl] acetate Chemical compound O=C1C(OC(C)=O)=C(C=2C=C3C=CC=CC3=CC=2)C(=O)C(OC(=O)C)=C1C1=CC=C(Br)C=C1 HYJZOIJTBMPKPU-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- VFSFCYAQBIPUSL-UHFFFAOYSA-N cyclopropylbenzene Chemical compound C1CC1C1=CC=CC=C1 VFSFCYAQBIPUSL-UHFFFAOYSA-N 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 102000047882 human INSR Human genes 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- DGQOCLATAPFASR-UHFFFAOYSA-N tetrahydroxy-1,4-benzoquinone Chemical compound OC1=C(O)C(=O)C(O)=C(O)C1=O DGQOCLATAPFASR-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/28—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of CHx-moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C46/00—Preparation of quinones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0201409A FR2835523B1 (fr) | 2002-02-06 | 2002-02-06 | Nouveaux derives de 3-aryl-2,5-dihydroxy-1,4-benzoquinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| PCT/FR2003/000331 WO2003066561A1 (fr) | 2002-02-06 | 2003-02-04 | Nouveaux derives de 3-aryl-2,5-dihydroxy-1,4-benzoquinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA79448C2 true UA79448C2 (en) | 2007-06-25 |
Family
ID=27619936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20040907252A UA79448C2 (en) | 2002-02-06 | 2003-04-02 | Derivatives of 3-aryl-2,5-dihydroxy-1,4-benzoquinone, method for synthesis and pharmaceutical composition |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20050085644A1 (ko) |
| EP (1) | EP1472208A1 (ko) |
| JP (1) | JP4098248B2 (ko) |
| KR (1) | KR100605805B1 (ko) |
| CN (1) | CN1274655C (ko) |
| AR (1) | AR038397A1 (ko) |
| AU (1) | AU2003226860B9 (ko) |
| BR (1) | BR0307465A (ko) |
| CA (1) | CA2474533A1 (ko) |
| EA (1) | EA006775B1 (ko) |
| FR (1) | FR2835523B1 (ko) |
| GE (1) | GEP20063900B (ko) |
| HK (1) | HK1078566A1 (ko) |
| MA (1) | MA27103A1 (ko) |
| MX (1) | MXPA04007684A (ko) |
| NO (1) | NO20043532L (ko) |
| NZ (1) | NZ534099A (ko) |
| PL (1) | PL370773A1 (ko) |
| UA (1) | UA79448C2 (ko) |
| WO (1) | WO2003066561A1 (ko) |
| ZA (1) | ZA200405446B (ko) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103058846B (zh) * | 2013-01-17 | 2014-07-30 | 福州大学 | 一种源于棘孢曲霉的苯醌衍生物及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3586910T2 (de) * | 1984-01-26 | 1993-05-19 | Otsuka Pharma Co Ltd | 1,4-benzochinon-derivate und benzol-derivate und verfahren zu ihrer herstellung. |
| US7057052B2 (en) * | 2002-09-26 | 2006-06-06 | Duke University | Heterocyclic quinones as pharmaceutical agents |
-
2002
- 2002-02-06 FR FR0201409A patent/FR2835523B1/fr not_active Expired - Fee Related
-
2003
- 2003-02-04 KR KR1020047012152A patent/KR100605805B1/ko not_active IP Right Cessation
- 2003-02-04 EP EP03737340A patent/EP1472208A1/fr not_active Withdrawn
- 2003-02-04 WO PCT/FR2003/000331 patent/WO2003066561A1/fr active Application Filing
- 2003-02-04 PL PL03370773A patent/PL370773A1/xx unknown
- 2003-02-04 MX MXPA04007684A patent/MXPA04007684A/es not_active Application Discontinuation
- 2003-02-04 GE GEAP8395A patent/GEP20063900B/en unknown
- 2003-02-04 CN CNB038031779A patent/CN1274655C/zh not_active Expired - Fee Related
- 2003-02-04 US US10/503,527 patent/US20050085644A1/en not_active Abandoned
- 2003-02-04 CA CA002474533A patent/CA2474533A1/fr not_active Abandoned
- 2003-02-04 JP JP2003565937A patent/JP4098248B2/ja not_active Expired - Fee Related
- 2003-02-04 BR BR0307465-0A patent/BR0307465A/pt not_active IP Right Cessation
- 2003-02-04 NZ NZ534099A patent/NZ534099A/en unknown
- 2003-02-04 EA EA200400992A patent/EA006775B1/ru not_active IP Right Cessation
- 2003-02-04 AU AU2003226860A patent/AU2003226860B9/en not_active Ceased
- 2003-02-06 AR ARP030100368A patent/AR038397A1/es not_active Application Discontinuation
- 2003-04-02 UA UA20040907252A patent/UA79448C2/uk unknown
-
2004
- 2004-07-08 ZA ZA200405446A patent/ZA200405446B/en unknown
- 2004-07-21 MA MA27795A patent/MA27103A1/fr unknown
- 2004-08-24 NO NO20043532A patent/NO20043532L/no not_active Application Discontinuation
-
2005
- 2005-11-21 HK HK05110489A patent/HK1078566A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100605805B1 (ko) | 2006-08-01 |
| EA200400992A1 (ru) | 2005-02-24 |
| CN1628088A (zh) | 2005-06-15 |
| FR2835523A1 (fr) | 2003-08-08 |
| FR2835523B1 (fr) | 2004-04-16 |
| CN1274655C (zh) | 2006-09-13 |
| AR038397A1 (es) | 2005-01-12 |
| GEP20063900B (en) | 2006-08-10 |
| HK1078566A1 (en) | 2006-03-17 |
| AU2003226860A1 (en) | 2003-09-02 |
| JP4098248B2 (ja) | 2008-06-11 |
| AU2003226860B9 (en) | 2008-08-14 |
| CA2474533A1 (fr) | 2003-08-14 |
| MXPA04007684A (es) | 2005-07-13 |
| PL370773A1 (en) | 2005-05-30 |
| JP2005517001A (ja) | 2005-06-09 |
| US20050085644A1 (en) | 2005-04-21 |
| KR20040086352A (ko) | 2004-10-08 |
| NO20043532L (no) | 2004-08-24 |
| EP1472208A1 (fr) | 2004-11-03 |
| AU2003226860B8 (en) | 2008-07-10 |
| MA27103A1 (fr) | 2004-12-20 |
| WO2003066561A1 (fr) | 2003-08-14 |
| BR0307465A (pt) | 2004-11-09 |
| EA006775B1 (ru) | 2006-04-28 |
| AU2003226860B2 (en) | 2008-06-26 |
| ZA200405446B (en) | 2005-07-08 |
| NZ534099A (en) | 2006-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4674088B2 (ja) | Ｇｓｋ３で選択的な阻害作用を示す新規な化合物 | |
| JP2008056688A (ja) | ピペリジン及びピロリジン | |
| BG62023B2 (bg) | Тетрахидробензтиазоли,метод за получаването и приложението им като междинни продукти или като лекарствени средства | |
| WO2012070114A1 (ja) | Ｎｐｙ ｙ５受容体拮抗作用を有するスルファミド誘導体 | |
| NO154883B (no) | Analogifremgangsmaate ved fremstilling av nye, terapeutisk aktive 2-acylaminomethyl-1,4-benzodiazepiner. | |
| KR101449348B1 (ko) | Ｋｖ７ 칼륨 채널 개방제로서의 피페리디닐 피리미딘 아미드 | |
| HU191161B (en) | Process for production of derivatives of tieno /2,2-a/ piramidin and their salts | |
| EP3266783A1 (en) | Derivatives of aza adamantanes and uses thereof | |
| SK147897A3 (en) | Azacycloalcane derivatives, preparation thereof and their applications in therapy | |
| FR2751649A1 (fr) | Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| UA79448C2 (en) | Derivatives of 3-aryl-2,5-dihydroxy-1,4-benzoquinone, method for synthesis and pharmaceutical composition | |
| JPS61218571A (ja) | 新規ラクタム誘導体及び新規チオラクタム誘導体並びに抗炎症剤 | |
| SK11372001A3 (sk) | Piperidínové a piperazínové deriváty ako inhibítory vzniku a'beta' fibríl | |
| AU2010212704A1 (en) | Substituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives, preparation thereof, and therapeutic use thereof | |
| MXPA05004793A (es) | Nuevos derivados de 2,3-dihidro-4(1h)-piridinonas, su metodo de preparacion y las composiciones farmaceuticas que lo contienen. | |
| NZ205181A (en) | 2-methyl-lyserg-8-yl ethers and thioethers,a method for their preparation and pharmaceutical compositions which contain them | |
| MXPA06001130A (es) | Derivados de 7-indolilsulfonamidas, su preparacion y su uso como moduladores de 5-ht-6. | |
| JP4008059B2 (ja) | 松果体ホルモン作用薬 | |
| EP3998107A1 (en) | Method for producing insulin-producing cell using dihydroindolizinone derivatives | |
| NO160712B (no) | Analogifremgangsm te for fremstilling av terapeutisk aktive benzotiazepin-forbindelser. | |
| JP2685880B2 (ja) | ７―オキソシクロペンタ〔ｄ〕ピリミジン誘導体 | |
| US3812170A (en) | N-(3,3-diphenyl-3-cyanopropyl)-ureas | |
| EP3089975B1 (en) | Novel imidazolidine-2, 4-dione derivatives | |
| US3546333A (en) | D-glucofurano amidazoline anti-inflammatory agents | |
| UA73916C2 (en) | Novel aryloxyalkyldialkylamines |